Monitoring antimicrobial resistance in pneumonia patients using metagenomics
Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients: a Genomic Epidemiology Study
Shanghai General Hospital, China · NCT06566898
This study is trying to understand how different germs and their resistance to antibiotics affect patients with mild and severe pneumonia to improve diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Sex | All |
| Sponsor | Shanghai General Hospital, China (other) |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06566898 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the microbiome and antimicrobial resistance genes in patients with severe and mild pneumonia. It will recruit patients from four hospitals in China over a six-year period, utilizing next-generation sequencing to gather comprehensive data on pathogen diversity and resistance. The study will focus on understanding the differences in microbiome composition and resistance profiles between severe and mild cases of pneumonia. By employing advanced metagenomic techniques, the research seeks to enhance clinical diagnosis and treatment strategies for pneumonia.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with either severe or mild pneumonia based on established clinical guidelines.
Not a fit: Patients whose biological samples are contaminated or do not meet the specified volume criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment options for pneumonia patients by providing insights into antimicrobial resistance.
How similar studies have performed: Other studies utilizing metagenomics to analyze microbial communities and resistance patterns have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011. * Clinical examination was performed, and there was biospecimen (nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage fluid, sputum, blood, hydrothorax, lung tissue) remaining in the clinical microbiological examination. Exclusion Criteria: * Patients whose biological samples may be contaminated; * Patients with alveolar lavage fluid or hydrothorax volume less than 200μl.
Where this trial is running
Shanghai, Shanghai Municipality
- Mei Kang — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Mei Kang, MPH — Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Study coordinator: Mei Kang, MPH
- Email: mei.kang@shgh.cn
- Phone: 18501709576
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pneumonia, Next-generation Sequencing, Microbiome, Antimicrobial Resistance, Next-generation sequencing